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Synopsis and graphical abstract 
Platinum ferrocenyl-phosphonate complexes [Fc(CH2)nPO3Pt(PPh3)2] [5, n = 0;  6, n = 1; 7, n = 
2;  Fc = (5-C5H4)Fe(
5
-C5H5)] and the dinuclear phosphonate-bridged complex [1,1’-
Fc’{PO3Pt(PPh3)2}2] 9 [Fc’ = Fe(
5
-C5H4)2] have been synthesised, and complexes 6, 7 and 9 
have been characterized by X-ray structure determinations; moderate activity against P388 
leukaemia cells is exhibited by 6 and 7, but the parent phosphonic acids are inactive. 
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Abstract 
 
Platinum ferrocenyl-phosphonate complexes, containing four-membered Pt-O-P(O)-O 
rings, have been synthesised by the reactions of cis-[PtCl2(PPh3)2] with the ferrocene-derived 
phosphonic acids Fc(CH2)nP(O)(OH)2 (n = 0-2) [Fc = (
5
-C5H4)Fe(
5
-C5H5)] and 1,1’-
Fc’[P(O)(OH)2]2 [Fc’ = Fe(
5
-C5H4)2] in the presence of Ag2O.  The complexes have been 
characterised by NMR spectroscopy, together with crystal structure determinations on 
[Fc(CH2)nPO3Pt(PPh3)2] (n = 1,2) and [1,1’-Fc’{PO3Pt(PPh3)2}2].  The complexes 
[Fc(CH2)nPO3Pt(PPh3)2] (n = 1,2) show moderate activity against P388 leukaemia cells, 
whereas the parent phosphonic acids are inactive. 
 
Keywords:  Platinum complexes;  Phosphonate complexes;  Antitumour activity;  Crystal 
structures 
 
1.  Introduction 
 
Due to the efficacy of various platinum complexes as antitumour agents a wide variety of 
platinum complexes have been screened for antitumour activity.  Among these are complexes 
containing phosphonate ligands, [1] which include, for example, complexes effective against 
osteosarcoma, a specificity believed to be due to the affinity of the phosphonate groups for 
calcified tissue.[2]  A wide range of platinum complexes containing aminophosphonate [3] and 
other phosphonate [4] ligands have been described in the literature, many of which have 
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antitumour activity.  Relevant to the studies described in this paper, complexes of the type 1 
were synthesised by Kemmitt and co-workers by the reaction of cis-[PtCl2L2] (L= ancillary 
donor ligand, e.g. PPh3) with the phosphonic acid or phosphoric acid monoester and excess 
Ag2O (as a halide abstracting agent and base).[5] In this paper we extend this methodology to 
the synthesis of platinum phosphonate complexes using ferrocene-derived phosphonic acids 
which we have recently reported.[6] 
 
2.  Results and discussion 
 
2.1  Synthesis and characterisation 
 
Reactions of the ferrocenyl monophosphonic acids 2-4 with cis-[PtCl2(PPh3)2] and 
excess Ag2O in refluxing dichloromethane gives the platinum phosphonate complexes 5-7 
respectively in high yield, Scheme 1, while the corresponding reaction with the bis(phosphonic 
acid) 8 gives the binuclear complex 9, Scheme 2.  The products are air-stable pale yellow 
solids which crystallise with dichloromethane of crystallisation, and decompose when heated.  
Complexes 5-7 are soluble in organic solvents such as dichloromethane and chloroform, while 
9 is soluble in more polar solvents such as dimethylsulfoxide and methanol. In the case of 9, 
satisfactory elemental analyses could not be obtained, but confirmation of the product was 
achieved by NMR spectroscopy and an X-ray structure determination. 
The 
31
P-{
1
H} NMR spectra of the platinum phosphonate complexes are very 
distinctive, due to coupling between the phosphine and phosphonate P atoms, and coupling of 
these P nuclei to the 
195
Pt nucleus.  
31
P NMR data are summarised in Table 1.  Values of 
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1
J(PtP) are consistent with PPh3 ligands trans to an oxygen donor, and data for the new 
complexes compare very favourably with those of the known complexes [Pt(O3PR)(PPh3)2] (R 
= Me, Ph, OPh);  data for R = Me are included in Table 1 for comparison. [5]  The positive ion 
electrospray mass spectra of 5-7 in dichloromethane showed a single low intensity [M + H]
+
 
ion at the expected m/z value (e.g. for 7 at m/z 1012).  Interestingly, spectra in methanol-water 
gave a low intensity [M + H]
+
 ion, with ions containing a cyclometallated PPh3 ligand 
observed in positive ion mode, and the parent phosphonic acid monoanion observed in 
negative ion mode, indicating dissociation of the platinum-phosphonate complex. 
 The structures of 6, 7 and 9 were determined by single-crystal X-ray diffraction studies, 
in order to confirm the bonding mode of the phosphonate ligand, and to provide a comparison 
between three closely related complexes.  Selected bond lengths and angles for the three 
structures are given in Tables 2 (6), 3 (7) and 4 (9), while the molecular structures and atom 
numbering schemes are given in Figures 1-3 respectively. Overall, the structure determinations 
were routine, and bond lengths and angles of the platinum-phosphonate moiety were consistent 
with those of [Pt(O3PPh)(PMePh2)2].[5]   
The structure of 6, when compared to that of the free acid [6] shows only minor 
changes in bond angles and lengths upon coordination to platinum.  Most notable are the 
reduction in the P=O bond length (1.566 Å in the free acid vs. 1.476 Å in 6), as the opportunity 
for hydrogen-bonding is removed, and the decrease in the O-P-O bond angle (108° in free acid 
vs. 101° in 12) due to the constrained nature of the four-membered Pt-O-P-O ring. The P=O 
bond lengths in all three structures are shorter than those of the metallacyclic P-O  bonds. The 
cyclopentadienyl rings of the ferrocene group adopt an eclipsed conformation and the C(1)-
C(11) bond lies in the plane of the cyclopentadienyl ring.   
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The principal difference in the structures of 6 and 7 lies in the orientation of the 
ferrocenyl unit with respect to the platinum coordination plane, as shown in Figure 4.  In 6, the 
ferrocenyl axis perpendicular to the cyclopentadienyl planes is almost parallel with the 
Pt…P(1) axis.  This minimises steric interactions between the ferrocenyl group and the phenyl 
rings of the PPh3 ligands.  In contrast, for 7 the corresponding ferrocenyl axis lies at an angle 
of ca. 60° to the Pt.…P(1) axis.  The additional CH2 spacer in 7 reduces steric congestion 
between the ferrocenyl and PPh3 groups, and the ferrocenyl group is subsequently able to adopt 
an orientation more strongly influenced by crystal packing forces than internal steric demands. 
 The cyclopentadienyl rings of 9 adopt a staggered conformation with the two PO3 units 
in an anti configuration to minimise steric interactions (Figure 5); the same configuration is 
also seen in the free acid. [6]  The core of this complex is very nearly centrosymmetric about 
the Fe atom;  bond lengths are essentially identical for the two halves of the molecule. The 
coordination planes of the platinum atoms are almost perpendicular to the plane of the 
ferrocenyl cyclopentadienyl rings.  
 All of the complexes possess a distorted platinum square plane.  Table 5 lists the twist 
and fold angles across the platinum square plane for compounds 6, 7 and 9 and 
[Pt(O3PPh)(PMePh2)2] for comparison.  The twist angle is a measure of the distortion about the 
platinum centre, while the fold angle is a measure of the coplanarity of the platinum and 
phosphonate centres.  The twist angle is larger in complexes 6 and 7 than in 
[Pt(O3PPh)(PMePh2)2] presumably due to the steric bulk of the ferrocenylphosphonate groups 
and PPh3 ligands compared to the phenylphosphonate and PMePh2 groups of 
[Pt(O3PPh)(PMePh2)2].  However, the twist angles in 9 are similar to that reported for 
[Pt(O3PPh)(PMePh2)2] but the fold angles are significantly larger. 
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2.2  Antitumour activity 
 
Given the interest in biological activity of platinum complexes [7], phosphonate 
complexes [1], and ferrocene-based complexes [8], the antitumour activity of the platinum 
phosphonate complexes described herein was considered worthy of preliminary investigation.  
Samples of 6 and 7 were assayed for activity against P388 leukaemia cells, with the activity of 
the parent phosphonic acids FcCH2PO3H2 and FcCH2CH2PO3H2 also undertaken for 
comparison.  IC50 data are listed in Table 6;  the phosphonic acids are essentially inactive, 
whereas the platinum complexes 6 and 7 show moderate activity.  
 
 
3.  Experimental 
 
General experimental procedures were as described previously [6];  reactions were carried out 
in solvents which were not deoxygenated. IR spectra were recorded as KBr disks. NMR 
spectra were recorded in CDCl3 solution unless otherwise stated.  The compounds cis-
[PtCl2(PPh3)2] [9], silver(I) oxide [10], and the phosphonic acids [6] were prepared as 
described previously.  The atom numbering schemes of the ferrocenyl groups is as previously 
reported. [6] 
Antitumour assays were carried out by the Marine Chemistry Group, University of 
Canterbury, NZ.  The samples were dissolved in 1:3 dichloromethane-methanol (typically 5 
mg mL
-1
; 2.5 mg mL
-1
 for 6), and a two-fold series of dilutions incubated for 72 hours with 
P388 (Murine Leukaemia) cells.  The IC50 value was determined by reduction of the yellow 
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dye MTT tetrazolium by healthy cells to the purple dye MTT formazan.  Mitomycin C was 
used as a positive control. 
 
Synthesis of platinum ferrocenylphosphonate complexes 
 
The general method used was that described by Kemmitt et al.[5]  A mixture of the phosphonic 
acid, cis-[PtCl2(PPh3)2] and excess silver(I) oxide was refluxed in dry dichloromethane.  The 
mixture was filtered to remove insoluble silver salts, the resulting yellow solution concentrated 
to ca. 2 mL and petroleum spirits added to precipitate the product as a pale yellow powder. 
 
[FcPO3Pt(PPh3)2] 5 
FcP(O)(OH)2 2 (0.017 g, 0.063 mmol), cis-[PtCl2(PPh3)2] (0.05 g, 0.063 mmol) and Ag2O 
(0.03 g, excess) in CH2Cl2 (5 mL) were refluxed for 1.5 h.  Workup gave 0.042 g (68%) of 5 as 
a yellow powder.  M.p. decomp. 138-142 °C.  Found:  C, 53.9;  H, 4.2.  
C46H39FeO3P3Pt.CH2Cl2 requires C, 52.8;  H, 3.9%.  
13
C-{
1
H} NMR,  69.47 (s, C4), 69.62 [d, 
3
J(PC) 12, C3], 71.95 [d, 
2
J(PC) 14, C2], 128.32-134.51 (m, PPh3).  
1
H NMR,  4.06 (5H, s, 
H4), 4.23 [2H, d, 
3
J(PH) 0.4, H2], 4.54 (2H, s, H3), 7.18-7.45 (30H, m, PPh3).  IR (cm
-1
):  
1882(w), 1211(w), 1174(w), 1098(m), 1027(w), 999(w), 927(m), 879(w), 610(m), 555(s), 
529(s). 
 
[FcCH2PO3Pt(PPh3)2] 6 
FcCH2P(O)(OH)2 3 (0.019 g, 0.07 mmol), cis-[PtCl2(PPh3)2] (0.053 g, 0.07 mmol) and Ag2O 
(0.03 g, excess) in CH2Cl2 (10 mL) were refluxed for 1 h.  Workup gave 0.057 g (86%) of 6 as 
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a pale yellow powder. Single crystals of the bis(dichloromethane) solvate were obtained by 
vapour diffusion of diethyl ether into a dichloromethane solution of the complex at 4 °C. 
Crystals visibly lose solvent on air-drying. M.p. decomp. 165-168 °C. Found:  C, 53.0;  H, 4.2.  
C47H41FeO3P3Pt.CH2Cl2 requires C, 53.2;  H, 4.0 %.  
13
C-{
1
H} NMR,  32.53 [d, 1J(PC) 117, 
CH2P], 66.74 (s, C3), 68.82 (s, C4), 70.28 (s, C2), 127.75-134.55 (m, PPh3).  
1
H NMR,  2.72 
[2H, d, 
2
J(PH) 18.7, CH2P], 4.02 (5H, s, H4), 4.04 (2H, s, H3), 4.10 (2H, s, H2), 7.13-7.31 
(30H, m, PPh3).  IR (cm
-1
):  1217(w), 1182(m), 1098(m), 999(w), 924(m), 612(w), 584(w), 
554(s), 530(s).   
 
[FcCH2CH2PO3Pt(PPh3)2] 7  
FcCH2CH2P(O)(OH)2 4 (0.040 g, 0.13 mmol), cis-[PtCl2(PPh3)2] (0.107 g, 0.13 mmol) and 
Ag2O (0.05 g, excess) in CH2Cl2 (10 mL) were refluxed for 1 h.  Workup gave 0.13 g (94%) of 
7 as a pale yellow powder. Single crystals were obtained by vapour diffusion of diethyl ether 
into a dichloromethane solution of the complex at 4 °C.  M.p. 209-212 °C (decomp.).  Found:  
C, 50.7; H, 4.1.  C48H43FeO3P3Pt.2CH2Cl2 requires C, 50.85;  H, 4.0%.  
13
C-{
1
H} NMR (d
6
-
DMSO),  25.09 (s, CH2CH2P), 32.70 [d, 
1
J(PC) 120, CH2P], 67.49 (s, C3), 68.07 (s, C2), 
68.75 (s, C4), 127.7-134.5 (m, PPh3).  
1
H NMR (d
6
-DMSO),  1.93 (2H, m, CH2P), 2.68 (2H, 
m, CH2CH2P), 4.05 (2H, s, H3), 4.09 (5H, s, H4), 4.13 (2H, s, H2), 7.2-7.5 (m, 30H, PPh3).  IR 
(cm
-1
):  1482(w), 1437(w), 1196(m), 1098(m), 999(w), 918(m), 595(m), 555(s), 529(s), 
512(m).   
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[1,1’-Fc’{PO3Pt(PPh3)2}2] 9 
1,1’-Fc’[P(O)(OH)2]2 8 (0.023 g, 0.067 mmol), cis-[PtCl2(PPh3)2] (0.106 g, 0.134 mmol) and 
Ag2O (0.10 g, excess) in CH2Cl2 (5 mL) were refluxed for 2 h.  Workup gave 0.088 g (74%) of 
9 as a pale yellow powder.  Single crystals of the complex suitable for an X-ray structure 
determination were obtained by vapour diffusion of diethyl ether into a dichloromethane-
methanol (9:1) solution of the complex at -20 °C.   M.p. 218-226 °C (decomp.).  Satisfactory 
microanalytical data could not be obtained. 
 1
H NMR (d
6
-DMSO),  4.08 (4H, s, H3), 4.31 
(2H, s, H2), 7.25-7.65 (60H, m, PPh3).    
 
Crystal structure determinations 
 
Data for 6 were collected on a Nicolet R3 diffractometer at the University of 
Canterbury, while data for 7 and 9 were collected on a Siemens Smart CCD diffractometer at 
the University of Auckland, and corrected for absorption using SADABS. [11] The structures 
were solved by Patterson methods for platinum and iron and developed routinely using the 
SHELX-97 program [12] with full-matrix least-squares refinement based on Fo
2
.  The 
structures of 6 and 7 each include two independent dichloromethane molecules of 
crystallisation.  Complete refinement of 9 was hampered by the presence of disordered solvent 
molecules.  A single methanol of crystallisation was successfully modelled but the final 
difference map contained several large peaks of electron density, some of which were able to 
be successfully modelled as carbon or oxygen atoms, but were unable to be refined in 
chemically sensible solvent molecules.  Despite this, an acceptable R1 of 0.0473 was achieved 
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and the structure of the platinum complex was refined without ambiguity.  All non-hydrogen 
atoms were refined using anisotropic temperature factors, while hydrogen atoms were placed in 
calculated positions. Crystallographic data and analysis parameters for the three structures are 
given in Table 7. 
Crystallographic data (excluding structure factors) for the three structures have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. 
CCDC-###### (6), ###### (7) and ###### (9). Copies of the data can be obtained free of 
charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44)1223-
336-033; e-mail: deposit@ccdc.cam.ac.uk). 
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Table 1.   
31P NMR data† for the platinum ferrocenylphosphonate complexes 
 
Complex  (31PPh3) 
1
J(PtP)  (31PO3) 
2
J(PtP)  
3
J(PP) 
             
5   8.2  3850  43.4  125  5.8 
6   7.2  3895  50.5  116  6.0 
7   7.9  3845  49.8  113  6.0 
9   8.1  3844  41.9  122  5.7  
[Pt(O3PMe)(PPh3)2] ¶ 7.25  3848  46.8  122  10 
 
 
¶  Data from ref. [5] 
† Recorded in CDCl3 solution, except for 9 in CH2Cl2 with an external D2O lock
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Table 2.  Selected bond lengths (Å) and angles (°) for [FcCH2PO3Pt(PPh3)2] 6.   
 
 
 
O(1)-Pt  2.081(3)  O(2)-Pt  2.075(3) 
Pt-P(2)   2.2253(10)  Pt-P(3)   2.2378(10) 
C(1)-C(11)  1.502(6)  C(1)-P(1)  1.807(5) 
P(1)-O(1)  1.563(3)  P(1)-O(2)  1.566(3) 
P(1)-O(3)  1.476(3) 
Cp Fe-C  average 2.032  range  2.014-2.042 
Cp  C-C  average 1.413  range  1.364-1.439 
 
O(1)-Pt-P(3)  93.18(8)  O(1)-P(1)-C(1) 110.41(19) 
O(2)-Pt-P(2)  99.01(8)  O(2)-P(1)-O(3) 116.42(17) 
P(2)-Pt-P(3)  97.31(4)  O(2)-P(1)-C(1) 105.69(19) 
O(1)-Pt-O(2)  71.14(11)  O(3)-P(1)-C(1) 107.41(19) 
Pt-O(1)-P(1)  93.21(13)  C(11)-C(1)-P(1) 116.8(3) 
Pt-O(2)-P(1)  93.34(13)  C(1)-C(11)-C(12) 127.0(4) 
O(1)-P(1)-O(2) 101.17(15)  C(1)-C(11)-C(15) 126.0(4) 
O(1)-P(1)-O(3) 115.29(18) 
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Table 3.  Selected bond lengths (Å) and angles (°) for [FcCH2CH2PO3Pt(PPh3)2] 7.   
 
O(1)-Pt  2.077(3)  O(2)-Pt  2.066(3)   
Pt-P(2)   2.2330(13)  Pt-P(3)   2.2656(11) 
C(1)-C(11)  1.505(8)  C(1)-C(2)  1.512(9)   
C(2)-P(1)  1.812(5)  P(1)-O(1)  1.571(3)   
P(1)-O(2)  1.577(3)  P(1)-O(3)  1.481(4)  
Cp Fe-C  average 2.041  range  2.028-2.063 
Cp  C-C  average 1.415  range  1.387-1.436  
 
O(1)-Pt-P(3)  96.51(9)  O(1)-P(1)-C(1) 109.4(4) 
O(2)-Pt-P(2)  94.32(10)  O(2)-P(1)-O(3) 115.6(2) 
P(2)-Pt-P(3)  98.45(5)  O(2)-P(1)-C(1) 105.3(2) 
O(1)-Pt-O(2)  71.00(0)  O(3)-P(1)-C(1) 110.2(2) 
Pt-O(1)-P(1)  93.8(2)  C(1)-C(2)-P(1) 115.3(4) 
Pt-O(2)-P(1)  93.99(14)  C(11)-C(1)-C(2) 115.9(5) 
O(1)-P(1)-O(2) 99.7(2)  C(1)-C(11)-C(12) 125.8(5) 
O(1)-P(1)-O(3) 115.9(2)  C(1)-C(11)-C(15) 126.9(6) 
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Table 4.  Selected bond lengths (Å) and angles (°) for [1,1’-Fc’{PO3Pt(PPh3)2}2] 9. 
 
Pt(1)-P(11)  2.258(2)  Pt(1)-P(12)  2.255(2) 
Pt(2)-P(21)  2.255(2)  Pt(2)-P(22)  2.242(2) 
P(1)-C(11)  1.801(7)  P(2)-C(21)  1.795(7) 
P(1)-O(11)  1.565(5)  P(1)-O(12)  1.576(5) 
P(1)-O(13)  1.501(5)  P(2)-O(21)  1.565(4) 
P(2)-O(22)  1.567(5)  P(2)-O(23)  1.505(5) 
O(11)-Pt(1)  2.097(4)  O(12)-Pt(1)  2.092(4) 
O(21)-Pt(2)  2.094(4)  O(22)-Pt(2)  2.086(4) 
Cp Fe-C  average 2.048  range  2.040-2.059 
Cp  C-C  average 1.425  range  1.413-1.436  
 
P(11)-Pt(1)-P(12) 99.91(6)  O(11)-P(1)-O(13) 115.1(2) 
P(21)-Pt(2)-P(22) 100.35(6)  O(21)-P(2)-O(23) 114.8(3) 
P(11)-Pt(1)-O(11) 98.06(13)  O(11)-P(1)-C(11) 109.1(3) 
P(21)-Pt(2)-O(21) 93.73(12)  O(21)-P(2)-C(21) 105.9(3) 
O(11)-Pt(1)-O(12) 70.62(17)  O(12)-P(1)-O(13) 114.2(3) 
O(21)-Pt(2)-O(22) 70.86(17)  O(22)-P(2)-O(23) 115.7(3) 
O(12)-Pt(1)-P(12) 91.33(13)  O(12)-P(1)-C(11) 107.9(3) 
O(22)-Pt(2)-P(22) 94.77(13)  O(22)-P(2)-C(21) 107.3(3) 
Pt(1)-O(11)-P(1) 93.4(2)  O(13)-P(1)-C(11) 109.0(3) 
Pt(2)-O(21)-P(2) 92.5(2)  O(23)-P(2)-C(21) 110.9(3) 
 17 
Pt(1)-O(12)-P(1) 93.3(2)  P(1)-C(11)-C(12) 124.9(6) 
Pt(2)-O(22)-P(2) 92.7 (2)  P(2)-C(21)-C(22) 126.5(5) 
O(11)-P(1)-O(12) 100.8 (2)  P(1)-C(11)-C(15) 127.6(5) 
O(21)-P(2)-O(22) 101.3(2)  P(2)-C(21)-C(25) 125.9(6) 
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Table 5.  Twist and fold angles (°) about the platinum centres for platinum 
phosphonate complexes. 
 
Compound   Twist angle†  Fold angle‡ 
           
6    9.2   11.3 
7    10.7   13.1 
9   Pt(1) 3.0   14.3 
   Pt(2) 5.5   17.0 
[Pt(O3PPh)(PMePh2)2] ¶ 2.2   12.9 
           
 
†Angle between P-Pt-P and O-Pt-O planes 
‡Angle between O-Pt-O and O-P-O planes 
¶ Data from ref. [5] 
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Table 6.   Antitumour (P388 leukaemia) assay data  
 
 
Compound    IC50 ¶ 
    ng mL
-1
  mM 
            
 
FcCH2PO3H2 3  538115  1915 
FcCH2CH2PO3H2 4  >62500  >219 
6    5838      5.8 
7    5046   5.0 
            
 
¶ Concentration of sample required to reduce the cell growth of the P388 leukaemia cell line by 
50%. 
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Table 7.  Crystal data and refinement details for [FcCH2PO3Pt(PPh3)2] 6, 
[FcCH2CH2PO3Pt(PPh3)2] 7 and [1,1’-Fc’{PO3Pt(PPh3)2}2] 9. 
 
Compound    6   7   9 
Empirical formula   C47H41FeO3P3Pt. C48H43FeO3P3Pt. C82H68FeO6P6Pt2. 
     2CH2Cl2  2CH2Cl2  CH3OH 
Crystal size (mm)   0.65x0.55x0.32 0.45x0.13x0.06 0.37x0.33x0.23 
Formula weight   1167.5   1181.53  1863.12 
Crystal system   Orthorhombic  Triclinic  Triclinic 
Space group    Pbca   P1
-
    P1
-
  
a (Å)     20.4241(9)  13.3696(2)  12.5981(1) 
b (Å)     18.4116(9)  14.3472(3)  16.3884(2) 
c (Å)     25.0622(13)  14.6522(2)  23.0691(2) 
 (°)     90   74.144(1)  93.815(1) 
 (°)     90   83.00(0)  104.156(1) 
 (°)     90   62.248(1)  111.58 
V (Å
3
)     9424.4(8)  2392.56(7)  4229.22(7) 
Z     8   2   2 
Dcalc (g cm
-3
)    1.646   1.64   1.463 
F(000)     4640   1176   1944 
(Mo-K) (mm-1)   3.64   3.36   3.63 
Temperature (K)   158(2)   200(2)   200(2) 
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2 range for data collection  6 < 2 < 53°  3 < 2 < 55°  2 < 2 < 54° 
Total reflections   24352   8329   17728 
Unique reflections   8654   7064   15684 
Tmin     0.6584   0.6386   0.4504 
Tmax     1.0000   0.8608   0.5494 
R1 [I > 2(I)]    0.0318   0.0283   0.0473 
wR2     0.0797¶  0.808§   0.1379☻ 
GOF     1.037   1.058   1.138 
Residual electron density (e Å
-3
)  
  Max.   1.227   0.741   3.462 
  Min.   -1.205   -0.853   -0.775 
             
 
¶ w = [2(Fo)
2
 + (0.0262P)
2
 + 37.6334P]
-1
  
§ w = [2(Fo)
2
 + (0.0406P)
2
 + 2.5846P]
-1
  
☻ w = [2(Fo)
2
 + (0.0673P)
2
 + 24.25P]
-1
 
 where P = (Fo
2
 + 2Fc
2
)/3 
 22 
Captions for Figures 
 
Fig. 1.  Molecular structure of [FcCH2PO3Pt(PPh3)2] 6.  Hydrogen atoms and the two CH2Cl2 
molecules of crystallization are omitted.  Ellipsoids are at the 50% probability level. 
 
Fig. 2.  Molecular structure of [FcCH2CH2PO3Pt(PPh3)2] 7.  Hydrogen atoms and the two 
CH2Cl2 molecules of crystallization are omitted.  Ellipsoids are at the 50% probability level. 
 
Fig. 3.  Molecular structure of [1,1’-Fc’{PO3Pt(PPh3)2}2] 9 with hydrogen atoms and solvent 
molecules of crystallization omitted.  Ellipsoids are shown at the 50% probability level. 
 
Fig 4.  Orientation of the ferrocenyl groups with respect to the platinum coordination planes in 
complexes 6 and 7, with all H atoms and phenyl rings omitted for clarity. 
 
Fig. 3.  Molecular structure of [1,1’-Fc’{PO3Pt(PPh3)2}2] 9 viwed down the C5H4-Fe-C5H4 axis 
showing the trans arrangement.  Phenyl rings and H atoms are omitted. 
  
